Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Kostas Biliouris, an analyst from BMO Capital, maintained the Hold rating on BridgeBio Pharma (BBIO – Research Report). The associated price ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

(In Nov. 22 story, corrects list price of Pfizer's drug to about $268,000 from $225,000 in paragraph 3) (Reuters) -The U.S.

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...